Thursday 16 October, 2025
Introduction: Cancer organoids are a 3D in vitro cancer model that faithfully mimic the characteristics of human tumors from which…
Read morePoster: Drug/Disease Modelling - Oncology
Translational modeling of tumor response to treatment: bridging preclinical to clinical studies
Thursday 16 October, 2025
Introduction Preclinical studies play an essential role in cancer research [1]. Patient-derived xenograft (PDX) models that implant patient tumor tissue…
Read moreJoint modeling of longitudinal and time-to-event data for earlier estimation of the primary endpoint in oncology clinical trials: A retrospective analysis of the ICARIA-MM clinical trial
Thursday 16 October, 2025
Introduction: Earlier assessment of clinical trial outcomes would allow earlier decision making, especially for trials of long duration, where models developed in…
Read moreContribution of modelling jointly progression-free survival and biomarker longitudinal data for therapeutic evaluation in oncology
Thursday 16 October, 2025
Objectives: Joint modeling has been increasingly used for therapeutic evaluation in oncology, as it allows the simultaneous fit of longitudinal…
Read moreEstimation of phase III trial outcome in oncology using joint models of longitudinal biomarker and time-to-event data
Thursday 16 October, 2025
CONTEXT: During drug development in oncology, a substantial amount of data is acquired to determine the safety and efficacy of…
Read moreBuilding evidence on the PKPD relationship with bispecific co-stimulatory antibodies using in vitro data: FAP-4-1BBL example
Thursday 16 October, 2025
Objectives: FAP-4-1BBL is a bispecific antibody currently in clinical development for solid tumors. FAP-4-1BBL exerts 4-1BB-associated T-cell activation only while…
Read morePreclinical in vivo data integrated in a modeling network informs a refined clinical strategy for a CD3 T-Cell bispecific in combination with anti-PD-L1
Thursday 16 October, 2025
Objectives: TYRP1-TCB is a CD3 T-cell bispecific (CD3-TCB) antibody developed for the treatment of advanced melanoma [1]. Upon dual binding…
Read moreDevelopment of a physiologically based pharmacokinetic model for intratumoral biodistribution of magnetic iron oxide nanoparticles
Thursday 16 October, 2025
Introduction: Iron oxide nanoparticles (NPs), particularly magnetic iron oxide (MIO) nanoparticles, may provide a potential therapeutic intervention in therapy, due…
Read moreUtilizing model informed drug development to support study design for Tovorafenib (DAY101), a novel, type II, pan RAF kinase inhibitor: a focus on longitudinal safety markers
Thursday 16 October, 2025
Objectives: Growth, survival, and differentiation, are key cell functions regulated by pathways such as the mitogen-activated protein kinase (MAPK) signaling…
Read moreLearning dose-response relationship via PK-TS-multistate clinical endpoints modeling framework: application to bintrafusp alfa in second-line non-small cell lung cancer patients
Thursday 16 October, 2025
Objectives: Bintrafusp alfa (BA) is a first-in-class bifunctional fusion protein targeting transforming growth factor-β and programmed death-ligand 1. This analysis…
Read more